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P-gpIn this study, we investigated the role of c-Myc in overcoming multidrug resistance (MDR) in human
ovarian and breast cancer cells by TRAIL. We showed that P-gp expressing MDR variants (Hey A8-MDR
and MCF7-MDR cells) with high level of c-Myc were highly susceptible to TRAIL treatment when
compared to their drug-sensitive parental human ovarian cancer Hey A8 and breast MCF-7 cells,
respectively. Up-regulation of DR5 TRAIL receptor and down-regulation of c-FLIP and the promotion of
caspase-dependent cell death, which contribute to TRAIL sensitization of MDR cells, were regulated by the
over-expressed c-Myc in the MDR cells. After targeted inhibition of c-Myc with speciﬁc siRNA, these
responses to TRAIL disappeared and TRAIL-induced apoptosis was also suppressed in MCF7-MDR cells.
Treatment with TRAIL signiﬁcantly reduced P-glycoprotein (P-gp)-mediated efﬂux of rhodamine123 in
both Hey A8-MDR and MCF7-MDR cells. Furthermore, TRAIL signiﬁcantly potentiated the cytotoxicity of
vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells,
which resulted in the reversal effect of TRAIL on the MDR phenotype. The present study shows for the ﬁrst
time that elevated c-Myc expression in the MDR cells plays a critical role in overcoming MDR by TRAIL
that can act as a speciﬁc sensitizer for P-gp substrate anticancer drug.d apoptosis-inducing ligand;
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The drug resistance that can develop in cancer cells often results
from increased expression of cell membrane transporters, which can
increase efﬂux of the anticancer drugs from the cancer cells, thus
lowering their intracellular concentrations [1,2]. The multidrug
resistance (MDR) phenotype exhibited by cancer cells is believed to
be the major obstacle for successful chemotherapy in cancer patients
[3,4]. MDR is a phenomenon whereby cancer cells exposed to one
cytotoxic agent develop cross-resistance to a range of structurally and
functionally unrelated compounds. This type of cross-resistance is due
to the expression of ATP binding cassette (ABC)-containing drug
efﬂux transporters that play important roles in regulating intracellulardrug concentrations and thus prevent the accumulation in cells of
therapeutic concentration of active agents. Of particular relevance to
cancer chemotherapy are the transporters P-glycoprotein (P-gp,
ABCB1) encoded by multidrug resistance 1 (MDR1) gene, multidrug
resistance (-associated) protein (MRP1, ABCC1), and breast cancer
resistance protein (BCRP, ABCG2). More than 80% of currently used
anticancer drugs can be transported by these three transporters, and
over-expression of these transporters renders multidrug resistance to
a broad spectrum of anticancer drugs [5]. Moreover, the growing
correlation between P-gp expression and a negative prognosis or poor
outcome for chemotherapy has sparked signiﬁcant interest in the
generation of inhibitors, and the intense search for compounds, which
can act to reverse MDR phenotype in cultured cells, in animal models,
and ultimately in patients has been reported [6]. Although several
inhibitors/modulators of ABC transporters have been developed,
cytotoxic effects and adverse pharmacokinetics have prohibited
their use and thereby clinical trials using these inhibitors have
generally produced disappointing results [7].
The ideal anticancer drugs are those that can selectively kill cancer
cells without harming normal cells. Currently, there are few agents
that are truly cancer cell speciﬁc in terms of efﬁcacy and induction of
cell death. Activation of death receptor signaling, particularly through
tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL)
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its potency, lack of signiﬁcant toxicity against normal cells, and ability
to kill cells with defective intrinsic apoptotic pathway [8]. TRAIL has
been demonstrated as an example of a molecule that selectively kills
transformed and cancer cells but not most normal cells [9]. After
binding of TRAIL to its cognate receptors, including DR4/DR5, the
receptors become trimerized and activated. The activated receptors
recruit an adapter protein (e.g., FADD) and a pro-caspase-8 molecule
to form a death-inducing signaling complex (DISC). Recruitment of
pro-caspase-8 to the DISC activates caspase-8, resulting in activation
of downstream caspases-3, -6, and -7, and apoptosis induction [10].
TRAIL has been shown to improve response to chemotherapy and
radiation when combined with these treatments [11,12]. However,
despite its promise, TRAIL resistance was established commonly and
limited its efﬁcacy in many preclinical models [13].
Myc proteins are key regulators of cell proliferation, apoptosis, and
differentiation [14]. Deregulation of c-myc gene contributes to the
genesis of a wide spectrum of human tumors and Myc is therefore an
attractive target for cancer treatment [15]. c-Myc promotes apoptosis
through the death receptor pathways at multiple junctions. c-Myc not
only modulates the extrinsic apoptotic pathway, but also participates
in the intrinsic pathways [16]. In addition, activation of c-Myc primes
mitochondria through a mechanism involving activation of Bak and
ampliﬁes the TRAIL-induced caspase-8-Bid signals to induce full-
blown apoptosis [17].
Previously, we demonstrated that the MDR variant of CEM cells
was hypersensitive to TRAIL due to up-regulation of DR5 and
concomitant down-regulation of c-FLIP and the c-Myc level of MDR
variants was positively correlated with the levels of P-gp as well as
DR5 and negatively correlated with the level of c-FLIPs [18]. It has
been reported that c-Myc could determine the TRAIL sensitivity via
direct repression of FLIP expression [19] and up-regulating cell surface
levels of the TRAIL death receptor DR5 [20]. Therefore, it was
necessary to determine if other multidrug-resistant cancer cells
would be also susceptible to TRAIL and sensitized to MDR-related
drugs by TRAIL, and this susceptibility would be associated with
increased c-Myc level in the MDR cells.
In this study, we demonstrated that MDR variants isolated from
human ovarian and breast cancer cell lines were highly susceptible
to TRAIL when compared to their drug sensitive parental cells and
TRAIL could be a new attractive P-gp disrupter to overcome MDR.
In addition, we revealed, for the ﬁrst time, that the overexpressed
c-Myc in the MDR cells was associated with the increased
susceptibility of MDR cells to TRAIL and was responsible at least
in part to the augmentation of the TRAIL-mediated reversal of
multidrug resistance.2. Materials and methods
2.1. Cell culture and reagents
For this study, we used highly metastatic human ovarian cancer
cell line Hey A8 and its multidrug resistant cell line Hey A8-MDR that
was generated by sequential exposure to increasing concentrations of
paclitaxel [21], and human breast cancer cell line MCF-7 and its
multidrug resistant cell line MCF7-MDR that was generated by
sequential exposure to increasing concentrations of Adriamycin
[22]. These four cell lines were kindly provided by Dr. Fiedler (MD
Anderson, TX, USA). These cells were maintained in 5% CO2 at 37 °C
and 95% humidity as adherent monolayers in DMEM supplemented
with 10% fetal bovine serum. The recombinant human soluble TRAIL
(Cat. No. 375-TEC/CF) and caspase-3 inhibitor, Z-DEVD-FMK were
purchased from R&D Systems (Minneapolis, MN). Vinblastine,
vincristine, doxorubicin, VP-16 and Rho123 were obtained from
Sigma-Aldrich (St. Louis, MO).2.2. MTT assay
Cell survival was measured either by counting viable cells by using
the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Sigma Chemical Company, St. Louis, MO) colorimetric dye-
reduction method. Exponentially growing cells (5×103 cells/well)
were plated in 96 well and incubated in growth medium treated with
indicated condition of TRAIL alone or in combination with other anti-
cancer drug at 37 °C. After 5 days, the medium was aspirated using
centrifugation andMTT-formazan crystals solubilized in 100 μl DMSO.
The optical density of each sample at 570 nm was measured using
ELISA reader (PowerWavex 340, Bio-Tek Instruments Inc., Winooski,
VT, USA). The optical density of the media was proportional to the
number of viable cells. Inhibition of proliferation was evaluated as a
percentage of control growth (no drug in the sample). All experiments
were repeated with at least two experiments in triplicate.
2.3. Flow cytometric analysis of TRAIL receptors
Cells (5×105 cells/well) treated with or without TRAIL were
centrifuged at 500×g, washed with phosphate-buffered saline
(PBS), and resuspended in 500 μl PBS. The cells were then incubated
with 5 μl mouse IgG, or anti-DR4 or -DR5 monoclonal mouse antibody
(1:100; R&D Systems, Minneapolis, MN, USA) for 2 h. After washing
with PBS, FITC-conjugated rabbit anti-mouse IgG (1:200; Sigma
Chemical Co., St. Louis, MO, USA) was added to the cell suspension
and incubated for 2 h on ice followed by washing with PBS. After
rinsing, the samples were analyzed by ﬂow cytometric analysis using
a FACSCalibur ﬂow cytometer (Becton Dickinson, San Jose, CA, USA).
The data were analyzed using the CellQuest program. To determine
whether TRAIL-induced apoptosis occurs through the death receptors,
cells were pretreated with the TRAIL-R1 (anti-DR4) or TRAIL-R2 (anti-
DR5) antibody (0.5 μg/ml, R & D Systems,Minneapolis, MN) 2 h before
treatment with 5 ng/ml TRAIL for 9 h. In control experiments, cells
were treated with normal IgG before TRAIL treatment. Apoptosis was
measured by Annexin V assay.
2.4. RT-PCR analysis
Total cellular RNA was isolated using RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer's protocol and the
levels of RNA transcripts were assessed with The Titan One Tube RT-
PCR System (MJ research Inc, NV, USA). One μg of total cellular RNA
was reverse transcribed usingMaloneymurine leukemia virus reverse
transcriptase (Invitrogen, Paisley, UK) with each dNTP and 1 μg oligo
dT. Ampliﬁcation of 1 μl of these cDNA by PCR was performed using
the following gene-speciﬁc primers: DR4 (forward), 5′-CTGAG-
CAACGCAGACTCGCTGTCCAC-3′ and (reverse), 5′-AAGGACAC GGCA-
GAGCCTGTGCCAT-3′; DR5 (forward), 5′-CTGAAAGGCATCTGCTCA
GGTG-3′ and (reverse), 5′-CAGAGTCTGCATTACCTTCTAG-3′; FLIPL
(forward), 5′-TTCCAGGCTTTCGGTTTCTT-3′ and (reverse), 5′-GTCC
GAAACAAGGTGAGGGT-3′; FLIPS (forward), 5′-ACCCTCACCTTGTTTC
GGAC-3′ and (reverse), 5′-CTTTTGGATTGCTGCTTGGA-3′; c-Myc (for-
ward), 5′-GAATGTGGCTATGGCTGGTG-3′ and (reverse), 5′-ACGG
GGCCATGCTTTATTAT-3′; MDR1 (forward), 5′-GGAAGCCAATGCCTAT-
GACT-3′ and (reverse), 5′-GAACCACTGCTTCGCTTTCT-3′; β-actin
(forward), 5′-CAGAGCAAGAGAGGCATCCT-3′and (reverse), 5′-TTGA
AGGTCTCAAACATGAT-3′. PCR products were analyzed by 2% agarose
gel electrophoresis and visualized with ethidium bromide staining.
2.5. Western blot analysis
Protein samples were separated by SDS-PAGE and blotted to
nitrocellulosemembrane (Hybond-ECL, GE Healthcare). Themembrane
was incubated with antibody as speciﬁed, followed by secondary
antibody conjugated with horseradish peroxidase. Speciﬁc antigen-
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(PerkinElmer, Life science). Western blot analysis was performed with
the following antibodies: anti-Bax, anti-caspase-3, anti-PARP, anti-Bcl-2,
anti-P-gp (Santa CruzBiotechnology, CA), anti-caspase-8, anti-caspase-9
(Cell signal, Danvers,MA), anti-c-Myc, anti-Bak (Epitomics, CA), anti-Bid
(R&D Systems, MN) and anti β-actin (Sigma-Aldrich) antibodies,
Secondary antibodies were obtained from GE Healthcare.
2.6. Preparation of siRNA transfection
The siRNA used for targeted silencing of c-Myc was (5′-CACAUCU-
CAUUUUUCCGUAdTdT-3′). MCF7-MDR cells were transfected with
0.1 μMsiRNA for 48 hbyoligofectamineaccording to themanufacturer's
protocol (Invitrogen, Carlsbad, CA). In brief, MCF7-MDR (2×105 cells/
well) were seeded in 6-well plates and added to the siRNA/
oligofectamine complex. Cells were incubated for 4 h at 37 °C in
serum free RPMI medium and then FBS was added. After 48 h, the cells
were treated with the indicated doses of TRAIL for 2–9 h and collected
for western blot analysis to determine the levels of c-Myc and other
indicated proteins.
2.7. Apoptosis assay
Cells (2×105 cells/ml) were treated with or without TRAIL and/or
indicated drug for 9 h and the cells were centrifuged and resuspended
in 500 μl of the staining solution containing Annexin V ﬂuorescein
(FITC Apoptosis detection kit; BD ParMingen San Diego, CA) and
propidium iodide in PBS. After incubation at room temperature for
15 min, cells were analyzed by ﬂow cytometry. Annexin V binds to
those cells that express phosphatidyl serine on the outer layer of the
cell membrane, and propidium iodide stains the cellular DNA of those
cells that have a compromised cell membrane. This allows for the
discrimination of live cells (unstained with either ﬂuorochrome) from
apoptotic cells (stained only with Annexin V) and necrotic cells
(stained with both Annexin V and propidium iodide).
2.8. Flow-cytometric dye-efﬂux assay
The accumulation of rhodamine 123, a ﬂuorescent substrate of P-gp,
inMCF7-MDR andHey A8-MDR cells treatedwith orwithout TRAILwas
measuredusing aﬂowcytometer (FACScalibur, BDBiosciences, San Jose,
CA).MCF-7andMCF7-MDRcells treatedwith orwithoutTRAIL (5 ng/ml
for 9 h) or Hey A8 and Hey A8-MDR cells treated with or without TRAIL
(10 ng/ml for 4 h) were incubated with rhodamine 123 (0.5 μg/ml) at
37 °C for 30 min. After incubation, the cells were washed with ice-cold
PBS and further incubated at 37 °C for 3 h to allow P-gp-mediated drug
efﬂux or on ice (4 °C) as control. Cells were pelleted by centrifugation at
500×g and resuspended in PBS. Cellular ﬂuorescence was analyzed
immediately by using ﬂow cytometer.
2.9. Statistical analysis
The results obtained were expressed as the mean±S.E. of at least
three independent experiments. The statistical signiﬁcance of differ-
ences assessed using the Student's t-test. *pb0.05, **pb0.01, and
***pb0.001 were considered statistically signiﬁcant in all experiments.
3. Results
3.1. P-gp expressing MDR cells with high level of c-Myc are highly
susceptible to TRAIL-mediated cell death
Although the selective sensitivity of a few MDR and transfected
cell lines to TRAIL has been reported [18,23,24], it is necessary to ﬁnd
out new targets and understand molecular mechanisms to increase
sensitivity to TRAIL of various MDR malignant cells. To compare thesusceptibility of TRAIL-mediated cytotoxicity between drug-sensitive
human ovarian Hey A8 and breast MCF-7 cells and their drug-selected
MDR variants, Hey A8-MDR and MCF7-MDR cells, they were treated
with increasing concentrations of TRAIL and TRAIL-induced apoptosis
and cytotoxicity in these cells were determined by ﬂow cytometry
and MTT assay, respectively. As shown in Fig. 1A, Hey A8-MDR and
MCF7-MDR cells exhibited a marked sensitivity to TRAIL-induced
apoptosis and cytotoxicity in a dose dependent manner compared
with parental Hey A8 and MCF-7 cells, respectively.
Since it has been known that c-Myc not only renders cancer cells
sensitive to TRAIL-induced apoptosis [25] but also regulates the
expression ofMDR1 gene [26,27], we compared themRNA and protein
levels of c-Myc as well as MDR1/P-gp between the parent and their
MDR cells (Fig. 1B). The mRNA and protein levels of both c-Myc and
MDR1/P-gp were higher in Hey A8-MDR and MCF7-MDR cells than
their parental counterparts. This result indicated the possibility that
the increased sensitivity of MDR cells to TRAIL might be associated
with the increased level of c-Myc in MDR cells overexpressing P-gp.
Since TRAIL stimulates cancer cell death through the pro-apoptotic
receptors DR4/DR5 [11], we then explored whether the increased
TRAIL-induced apoptosis in P-gp-overexpressing MDR cells was
mediated via DR4 and/or DR5 death receptors (Fig. 2A). We found
that treating Hey A8-MDR cells with neutralizing antibody to TRAIL
receptor DR5 prior to TRAIL treatment inhibited signiﬁcantly TRAIL-
induced apoptosis, while the neutralizing anti-DR4 antibody did not
inhibit TRAIL-induced apoptosis in the MDR cells. Similar results were
observed in MCF7-MDR cells. Therefore, to correlate the inhibitory
effects of anti-DR5 neutralizing antibody on TRAIL-induced apoptosis
in the MDR cells with cell surface expression of DR5, we examined the
cell surface expression of DR4 and DR5 in the presence or absence of
TRAIL in the MDR cells. The basal levels of DR4 and DR5 were low in
both MDR cells. After treatment with TRAIL, the surface expression of
DR5 but not DR4 was signiﬁcantly up-regulated in both Hey A8-MDR
and MCF7-MDR cells (Fig. 2B).
Wenext assessed themRNA levels of c-Myc, DR4/DR5 and c-FLIPL/S in
bothMDR cells treatedwith orwithout TRAIL using RT-PCR (Fig. 3). Both
Hey A8-MDR andMCF7-MDR cells showed that the basalmRNA levels of
c-Myc and DR5 were signiﬁcantly higher than in their parental
counterparts. Moreover, the mRNA level of DR5 was enhanced in both
MDR cells compared with those in parental counterparts after treatment
with TRAIL whereas the mRNA level of DR4 in both MDR cells was not
modulatedbyTRAIL.Wenext compared theexpression levels of c-FLIPL/S,
the important downstream regulators of death receptor-mediated
apoptosis [28], between theMDR and their parental cells in the presence
or absence of TRAIL. Interestingly,we found that the basalmRNA levels of
both c-FLIPL and c-FLIPS were signiﬁcantly decreased in both Hey A8-
MDR andMCF7-MDR cells comparedwith their respective parental cells,
and themRNA level of c-FLIPLwas further decreased by TRAIL treatment.
Therefore, our results suggest that the high susceptibility of MDR cells to
TRAILmight be related to the up-regulation of DR5 and down-regulation
of c-FLIP.
3.2. Caspase-dependent apoptotic pathways are activated in MDR cells
by treatment with TRAIL
We determined if the high susceptibility to TRAIL of MDR cells was
accompanied by activation of caspases (Fig. 4). Consistent with the
hypersensitive response of Hey A8-MDR cells to TRAIL-induced cell
death, the cleavage and activation of procaspase-8, which are initiator
caspases linked to receptor-mediated apoptotic pathway, are elevated
in Hey A8-MDR cells as compared to Hey A8 cells after treatment with
TRAIL. In the case of caspase-9 that has been linked to the
mitochondrial death pathway, treatment of Hey A8-MDR cells with
TRAIL resulted in signiﬁcant induction of proteolytic processing of
caspase-9 to its active form compared to Hey A8 cells. Caspase-3 is a
downstream effector caspase and can be activated by both caspase-
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procaspase-3 and PARP, a hallmark of caspase-dependent apoptosis,
was remarkably increased in TRAIL-treated Hey A8-MDR cells
compared to Hey A8 cells. We also investigated whether the
modulation of proapoptotic Bax and anti-apoptotic Bcl-2 proteins
was involved in the TRAIL-induced apoptosis of the MDR cells.
Although the basal level of Bax and Bcl-2 were decreased and
increased in Hey A8-MDR cells as compared to Hey A8 cells,
respectively, up-regulation of Bax and down-regulation of Bcl-2A
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and TRAIL-induced DR5 surface expression in MDR cells
To investigate the direct role of c-Myc in regulating the
susceptibility of theMDR cells to TRAIL, we used siRNA to knockdown
c-Myc expression and determined the effect of c-Myc suppression on
susceptibility to TRAIL of MDR cells. After transfection of Hey A8-
MDR or MCF7-MDR cells with siRNA against c-Myc or scrambled
siRNA as a control, the transfectant was treated with TRAIL.
Suppression of c-Myc expression signiﬁcantly attenuated TRAIL-
induced apoptosis in both Hey A8-MDR andMCF7-MDR cells (Fig. 5).
Similarly, knockdown of c-Myc also reduced TRAIL-induced cytotox-
icity in both MDR cells (data not shown).Since we found up-regulation of DR5 cell surface expression in
MDR cells after TRAIL treatment (Fig. 2B), we examined whether
suppression of c-Myc could affect DR5 cell surface expression and
caspase activity in TRAIL-treated MDR cells (Fig. 6). As expected,
knockdown of c-Myc blocked the induction of DR5 in MCF7-MDR
cells following TRAIL treatment (Fig. 6A). Since it has been shown
that c-Myc activates the mitochondrial pro-apoptotic Bcl-2 protein
Bak, which is required for TRAIL-induced Bax activation [31], we
determined whether suppression of c-Myc could down-regulate
the expression of Bak and caspase activation in MCF7-MDR cells
(Fig. 6B). The siRNA-mediated c-Myc knockdown resulted in the
signiﬁcant decrease of Bak expression in MCF7-MDR cells. It has
been reported that c-Myc acts as a gatekeeper of the caspase
feedback ampliﬁcation loop and c-Myc-mediated priming of the
mitochondrial pathway enables weak caspase-8 signals to activate
effector caspases and establish a death executing caspase feedback
ampliﬁcation loop [17]. In our study, knockdown of c-Myc
inhibited TRAIL-induced activation of caspase-8, -9 and caspase-3
and subsequent PARP cleavage also resulted in the introduction of
c-FLIP. These results suggested that the up-regulated c-Myc could
be responsible for increased susceptibility of MDR cells to TRAIL.
Especially, the higher susceptibility to TRAIL of MCF7-MDR cells
might be due to the overexpressed c-Myc as well as caspase 3,
which is deﬁcient in MCF-7 cells, since activation by TRAIL of
upstream pro-caspases such as pro-caspase 8 and 9 was much
more sensitive to TRAIL in MCF7-MDR cells than MCF-7 cells, and
was prevented by knockdown of c-Myc.3.4. Inhibition of P-gp efﬂux function by TRAIL is associated with
degradation of P-gp
Since it has been reported that 170-kDa P-gp is cleaved during
apoptosis of VBL100 human T-lymphoblastoid CEM cells induced
by LY294002 and H2O2 [32] and our data showed prominent
activation of caspase-3 in MDR cells after treatment with TRAIL,
we determined whether the increased P-gp could be degraded by
TRAIL in c-Myc over-expressing MDR cells, which were hyper-
sensitive to TRAIL-induced apoptosis. When Hey A8-MDR and
MCF7-MDR cells were treated with TRAIL, the overexpressed P-gp
was cleaved by treatment with TRAIL in dose dependent manner,
and this was prevented by pretreatment with a caspase-3-speciﬁc
inhibitor Z-DEVD-FMK (Fig. 7A), indicating the possibility that P-
gp cleavage and inactivation is mediated by TRAIL-induced
activation of caspase-3 in c-Myc-overexpressing MDR cells.
We further determined whether degradation of P-gp by
treatment with TRAIL results in inhibition of P-gp-mediated
efﬂux function of the MDR cells, using a ﬂow cytometric
functional efﬂux assay based on the extrusion of rhodamine 123
(Rho 123), a ﬂuorescent P-gp substrate (Fig. 7B). P-gp functions
optimally near 37 °C, but it is inactive at 4 °C. When P-gp
expressing Hey A8-MDR cells were preloaded with Rho123 and
incubated at 4 °C, they retained the dye and consequently had
high ﬂuorescence levels. On the contrary, Hey A8-MDR cells
incubated at 37 °C excreted the dye and showed the reduction of
ﬂuorescence intensity. However, treatment with TRAIL signiﬁ-
cantly reduced Rho123 efﬂux in the MDR cells. But, there were no
differences in the ﬂuorescence intensity between the three
experimental conditions, when we performed this functional
assay on Hey A8 cells without P-gp expression. Similar results
were observed in TRAIL-treated MCF7-MDR cells. TRAIL effectively
inhibited P-gp efﬂux function in MCF7-MDR cells. These results
indicate that the increased cleavage of P-gp by TRAIL might be
dependent on caspase-3 activity in MDR cells with high
expression of c-Myc, which leads to the inhibition of P-gp efﬂux
function in MDR cells.
Hey A8-MDR MCF7-MDR
Fig. 5. Suppression of c-Myc inhibited TRAIL-induced apoptosis in MDR cells. Hey A8-MDR (left) or MCF7-MDR (right) cells were transfected with a siRNA against c-Myc or
scrambled siRNA as a control. After 48 h, the transfectants were treated with indicated doses of TRAIL for 9 h. Induction of apoptosis was performed by Annexin V analysis. Each bar
represents the mean±S.D. of triplicate experiments. **pb0.01.
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Fig. 6. Suppression of c-Myc blocked the DR5 cell surface expression and caspase activation by TRAIL in MDR cells. (A) MCF7-MDR cells transfected with c-myc siRNA or scrambled
siRNA were treated with 5 ng/ml TRAIL for 2 h. To determine the surface expression of DR4/DR5, samples were stained with control IgG or anti-DR4/DR5 antibody (1:100), and
subsequently labeled with FITC-conjugated secondary antibodies (1:200). The cell surface expression was measured by a ﬂow cytometer. Shaded and unshaded peaks correspond to
control and speciﬁc stainings, respectively. (B) MCF7-MDR cells transfected with c-myc siRNA or scrambled siRNAwere treated with or without TRAIL (0.5- and 5 ng/ml for 9 h), and
thereafter, the levels of c-Myc, Bak, Caspases (caspase-8, -9 and -3), PARP and c-FLIPL/S were performed by western blot analysis. Actin was used as a loading control.
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Fig. 7. Inhibition of P-gp efﬂux function by TRAIL is associated with down-regulation and degradation of P-gp by TRAIL-induced caspase-3 activation. (A) The cell lysates obtained
from Hey A8-MDR and MCF7-MDR cells pretreated with or without 50 μM Z-DEVD-FMK, a speciﬁc caspase-3 inhibitor, for 3 h and then with TRAIL (1- and 5 ng/ml for 9 h) were
subjected to western blot analysis to monitor levels of P-gp, caspase-3 and PARP and their cleavage fragment (CF). (B) Flow cytometric assay of P-gp efﬂux activity in TRAIL-treated
MDR cells was based on extrusion of the ﬂuorescent P-gp substrate, rhodamine 123 (Rho123). The efﬂux activity of P-gp is highly temperature sensitive because it functions
optimally 37 °C but is inactive at 4 °C. Cell suspension isolated from Hey A8 and MCF-7 cells and its MDR variants treated with or without 10- and 5 ng/ml TRAIL for 4- and 9 h,
respectively. And then these are incubated with Rho123 and further incubated at 37 °C for 4 h (TREATED 37 °C as TRAIL-treated cells or CTRL 37 °C as TRAIL-untreated control) to
allow P-gp-mediated drug efﬂux or on ice as control (CTRL 4 °C).
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and reverses MDR
To overcome MDR, much attention has been focused on develop-
ing P-gp modulators with proper potency, selectivity and pharmaco-
kinetics [6,7]. In this study, we examined the effects of TRAIL as a new
candidate of P-gp modulator on growth inhibition of MDR cells and
MDR-reversing activity. Since TRAIL effectively induced P-gp degra-
dation, we investigated the combination effect of TRAIL on P-gp
substrate anticancer drugs in MDR cells (Table 1). The drug sensitivity
of vincristine (VCR), vinblastine (VBL), doxorubicin (DOX) and VP-16
known to be P-gp substrates was signiﬁcantly potentiated by TRAIL
treatment. Treatment of Hey A8-MDR cells with TRAIL (1 ng/ml)
caused about 14-, 6-, 4-, and 22-fold increase in the chemosensitivity
to VCR, VBL, DOX and VP-16, respectively. Similarly, the chemosensi-
tivity to VCR, VBL, DOX and VP-16 in MCF7-MDR cells was increased
about 13-, 15-, 16-, and 22-fold by pretreatment with TRAIL,
respectively, indicating that TRAIL could be a new attractivemodulator with inhibitory action on P-gp-mediated drug transport.
Therefore, these results strongly suggest that degradation and
inactivation of P-gp by TRAIL may be a cause of sensitization of both
Hey A8-MDR and MCF7-MDR cells to P-gp substrate anticancer drugs,
and thus the use of TRAIL in combination with P-gp substrate
anticancer drugs for growth inhibition in MDR cells might be effective
for overcoming multidrug resistance in human breast and ovarian
cancer cells.
4. Discussion
The multifactorial nature of MDR suggests that it may be
important to develop modulators that can simultaneously inhibit
both the function of the drug transporters and key signaling
pathways. In the present study, we showed that TRAIL could be a
new attractive therapeutic agent for P-gp-related MDR cancer cells
with high level of c-Myc. We found that the drug-selected MDR
variants, Hey A8-MDR and MCF7-MDR sublines, which were
Table 1
TRAIL potentiates the cytotoxicity of P-gp substrate anticancer drugs in MDR cells.
Cells Drugs (−) TRAIL (+) 1 ng/ml TRAIL
IC50 (nM)
Hey8-MDR VCR 880.7±26.40 63.1±3.39 (13.9)
VBL 198.0±8.72 34.2±1.50 (5.8)
DOX 107.2±4.06 24.4±0.95 (4.4)
VP-16 2072.8±33.84 94.1±4.89 (22.0)
MCF7-MDR VCR 210.3±4.53 16.1±0.34 (13.1)
VBL 569.6±30.17 37.7±2.41 (15.1)
DOX 327.9±14.51 19.9±0.77 (16.5)
VP-16 387.4±20.46 17.7±0.44 (21.9)
Hey A8-MDR and MCF7-MDR cells (4×103 cells/well) were treated with graded single
doses of vincristine(VCR), vinblastine (VBL), doxorubicin (DOX), or VP-16 after
pretreatment of TRAIL (1 ng/ml for 4 h). The percentage of cell survival after
combined treatment of TRAIL with the agent that interacts with P-gp was
determined after 5 days incubation using the MTT assay. The 50% inhibitory
concentration (IC50) of each anticancer drug, which reduced cell growth by 50%, was
determined from growth inhibition plots that caused a 50% reduction in cell viability.
Data shown are the mean±S.D. of two experiments carried out in triplicates.
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cancer cell lines, respectively, were highly susceptible to TRAIL and
had an increased level of c-Myc, when compared to their
respective parental counterpart. Previously we also observed that
the MDR variants of human leukemic CEM cells with an increased
level of c-Myc were hypersensitive to TRAIL [18]. Moreover, we
revealed that up-regulation of DR5 TRAIL receptor, down-regula-
tion of c-FLIP and the increased caspase-dependent cell death,
which are associated with increased susceptibility of MDR cells to
TRAIL, were attributed to the over-expressed c-Myc in the MDR
cells.
Myc has been examined as a prognostic, predictive or therapeutic
target in breast cancer, which is the most common female malignancy
in many industrialized countries. c-Myc or N-Myc overexpression in
breast cancer is observed with a frequency of 45% or 25%, respectively
[33,34]. In the case of ovarian cancer, c-Myc or L-Myc overexpression
is observed with a frequency of around 40% [35,36]. These data
implicated that ampliﬁcation and/or overexpression of Myc family
genes is related with pathogenesis and clinical outcome of human
breast and ovarian cancers.
On the other hand, elevated expression of ABC transporters is
frequently found in breast cancers and correlations between response
to chemotherapy and expression of P-gp or MRP1 have been observed
in some cases, suggesting that ABC transporters may contribute to
chemoresistance in breast cancers [37]. However, attempts to
modulate the activities of these transporters using reversal agents
have met limited success. Novel strategies for improving chemother-
apeutic efﬁcacies through targeted interventions of ABC transporter
are necessary [38].
Recently, it was reported that Myc proteins positively regulated
MDR1 gene promoter by interaction with E-box-related motifs and
altered ABC transporter expression [39]. Since direct and coordi-
nate regulation of ABC transporter genes involving P-gp/MDR1 by
Myc factors generates speciﬁc transcription signatures that
signiﬁcantly affect the MDR phenotype of cancer cells [40],
determination of Myc expression levels in cancer may be
important for prediction of ABC transporter gene transcription
proﬁles and possibly for the choice of appropriate therapeutic
protocols to treat cancer patients.
Myc can enhance receptor signaling and also amplify the death
signal at the mitochondria. In the case of TRAIL signaling, c-Myc
controls the caspase feedback ampliﬁcation loop, resulting in
mitochondrial ampliﬁcation of the caspase-8-Bid signals [17], and
also c-Myc was shown to repress FLIP transcription, causing increased
caspase-8 activation [19].
In this study, we have demonstrated that c-Myc overexpressed in
multidrug-resistant cells including Hey A8-MDR and MCF7-MDR
cells is closely associated with the increased susceptibility of the
MDR cells to TRAIL, and that targeted inhibition of c-Myc expression
in the MDR cells blocked TRAIL-induced up-regulation of DR5 cell
surface expression, and led to reduction of TRAIL-induced caspase-8,
-9 and -3 activation and conversely elevation of c-FLIP expression,
which attenuated TRAIL-induced apoptosis and cytotoxicity of Hey
A8-MDR and MCF7-MDR cells. These results indicated direct
regulation the susceptibility of MDR cells to TRAIL by c-Myc and
thus oncogenic overexpression of Myc in MDR cells could be a
potential biomarker for prediction of TRAIL sensitivity. However, the
mechanism that links c-Myc and the increased susceptibility of MDR
cells to TRAIL-mediated cell death was not understood. Therefore, it
is necessary to determine the critical role of c-Myc in the
susceptibility of MDR cells to TRAIL and MDR-reversing effect of
TRAIL on cancer cells.
Over-expression of P-gp encoded by the MDR1 gene is the
major molecular mechanism enhancing efﬂux pump for various
anticancer agents. P-gp can regulate the mitochondrion-depen-
dent apoptotic pathway, conferring resistance to a caspase-dependent apoptosis induced by antineoplastic agents [41].
Moreover, P-gp could be cleaved by caspase-3 during apoptosis
induced by a number of unrelated stimuli [32]. Here, we showed
that TRAIL treatment in both MCF7-MDR and Hey A8-MDR cells
overexpressing c-Myc resulted in dramatic increase in caspase-3
enzymatic activity, and consequently the cleavage of P-gp, which
was completely blocked by pretreatment with Z-DEVD-FMK, a
caspase-3-speciﬁc inhibitor. These results were in good agree-
ment with our previous result, which showed that degradation of
P-gp as well as DNA-PKcs during treatment of human leukemic
CEM/VLB100 MDR cells with TRAIL was a caspase-3 dependent
manner [18].
Since P-gp, a universally accepted biomarker of drug resistance,
is considered as a molecular target in multidrug-resistant cancer,
the inhibitors of drug efﬂux can increase drug accumulation and
reverse MDR phenotype in cultured cells and animal models has
led to the clinical development of a number of P-gp inhibitors [6].
P-gp inhibitors with low toxicity would be clinically useful for
drug resistance circumvention. Generation of the most recent
inhibitors employed combinatorial chemistry to produce potent
and selective P-gp inhibitors as MDR1-inverse compounds, which
can sensitize cancer cells that over-express P-gp. However,
currently available P-gp inhibitors lack the potency to completely
reverse the MDR phenotype at clinically achievable concentrations
even with third generation modulators (e.g. biricodar, zosuquidar,
and laniquidar) [42,43]. In our study, we found that P-gp mediated
efﬂux of Rho 123, a P-gp substrate, was signiﬁcantly reduced in
both Hey A8-MDR and MCF7-MDR cells by treatment with TRAIL
and thereby increased the accumulation of Rho 123 in the MDR
cells. Interestingly, our data showed that the cytotoxicity of P-gp
substrate anticancer drugs such as VLB, VCR, DOX and VP-16 was
signiﬁcantly enhanced in both Hey A8-MDR and MCF7-MDR cells
by pre-treatment with low dose (1 ng/ml) of TRAIL, which resulted
from inhibition of drug efﬂux function of P-gp via TRAIL-induced
P-gp cleavage, indicating that TRAIL selectively potentiated
cytotoxicity of P-gp substrate anticancer drugs and thus reverse
MDR in part through down-regulation and inactivation of P-gp.
The use of low dose of TRAIL with low toxicity may allow a new
paradigm of clinically useful drug resistance circumvention.
Therefore, our data suggest that TRAIL, which is nontoxic to the
majority of normal cell types, can be used in combination with
MDR-substrate anticancer drugs for sensitization of multidrug-
resistant human breast and ovarian cancers as a new approach to
reverse MDR.
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